This is a past event. Registration is closed. View other The Society of Gynecologic Oncology of Canada events.

Event DetailsEvent Details

Learning Objectives

  1. Review and critique the KEYNOTE-775 (endometrial cancer: pembrolizumab + lenvatinib) and KEYNOTE-826 (cervical cancer - pembrolizumab) studies
  2. Describe the treatment benefits observed in combination treatments that include immune checkpoint inhibitors
  1. Recognize key organ-specific toxicities unique to immune checkpoint inhibitors +/- tyrosine kinase inhibitors
  2. Outline practical management challenges for immunotherapy in gynecological malignancies

SpeakersSpeakers

HighlightsHighlights

2Speakers

Sponsors and PartnersSponsors and Partners

Organizer

Sponsors

TicketsTickets

GOC Member

Member Only
Individual Ticket

Non-GOC Member

Individual Ticket

Partner

Individual Ticket